{"url_path":"/sec/cik-0001263508/13dg/2026-05-11/000110465926058726","section_key":"body","section_title":"SCHEDULE 13D/A body","topic":"sec","document":{"doc_type":"SCHEDULE 13D/A","doc_date":"2026-05-11","source_url":"https://www.sec.gov/Archives/edgar/data/1263508/0001104659-26-058726-index.html","accession_number":"0001104659-26-058726","cik":"0001263508","ticker":null,"issuer_name":"BAKER BROS. ADVISORS LP","edgar_url":"https://www.sec.gov/Archives/edgar/data/1263508/0001104659-26-058726-index.html","primary_entity_key":"0001263508","primary_entity_name":"BAKER BROS. ADVISORS LP"},"word_count":30,"has_tables":true,"body_markdown":"EX-99.1\n2\ntm2613974d1_ex99-1.htm\nEXHIBIT 99.1\n\n**Exhibit 99.1**\n\n**Holder**** **\n**Shares of\nCommon Stock**** **** **\n**Percent of Class\nOutstanding**** **\n\n667, L.P.\n2,558,212\n1.3%\n\nBaker Brothers Life Sciences, L.P.\n27,928,891\n14.0%\n\nTotal\n30,487,103\n15.3%"}